Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07168902 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
A Phase 2 study of Glaucoma, sponsored by Bausch & Lomb Incorporated.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 228
- Enrollment target
- 8
- Study locations
NCT07168902 is a Phase 2 study of Glaucoma that is actively recruiting participants, run by Bausch & Lomb Incorporated. The registered enrollment target is 228 participants, below the 908-participant average among 92 other Glaucoma trials with a reported enrollment target (75% lower). The trial reports 8 study locations across 5 states.
The verdict
NCT07168902, a Phase 2 study of Glaucoma, is actively recruiting participants, sponsored by Bausch & Lomb Incorporated.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 228 participants
- Enrollment target
- 8
- Study locations
Study Summary
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults with Primary Open Angle Glaucoma or Ocular Hypertension
Conditions Studied
Interventions
- DRUG BL1107 Low dose
- DRUG BL1107 High dose
- DRUG Timolol maleate 0.5%
Study Locations (8)
Florida
- Levenson Eye Associates - Jacksonville
- Central Florida Eye Associates - Lakeland
- Lee Shettle Eye and Hearing - Largo
California
- Global Research Management, Inc. - Glendale
- Eye Research Foundation - Newport Beach
Massachusetts
- Andover Eye Associates - Andover
Pennsylvania
- Scott & Christie and Associates, PC - Cranberry Township
Tennessee
- Total Eye Care, P.A. - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 228 participants |
| Start Date | 2025-10-24 |
| Est. Completion | 2026-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07168902
The ClinicalTrials.gov registry entry for NCT07168902 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 228 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 908-participant average among 92 other Glaucoma trials with a reported enrollment target (75% lower). The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glaucoma appearing as the primary indexed condition, and to 3 interventions - of which BL1107 Low dose is the first listed.
NCT07168902 reports 8 study locations spanning 5 distinct geographic areas - top geographies include Florida, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07168902 about?
NCT07168902 is a clinical study titled "Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension". Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults with Primary Open Angle Glaucoma or Ocular Hypertension
What is the current status of trial NCT07168902?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 228 participants. The study started on 2025-10-24. Estimated completion is 2026-05.
What conditions does trial NCT07168902 study?
This clinical trial studies the following conditions: Glaucoma.
What interventions are being tested in trial NCT07168902?
The interventions under investigation include: BL1107 Low dose (DRUG), BL1107 High dose (DRUG), Timolol maleate 0.5% (DRUG).
Who is sponsoring clinical trial NCT07168902?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07168902 being conducted?
This trial has 8 study locations across California, Florida, Massachusetts, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
RECRUITING · Phase 2
-
Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration
ACTIVE NOT RECRUITING · Phase 2
-
Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma
ACTIVE NOT RECRUITING · Phase 2
-
Circadian Rhythms of Aqueous Humor Dynamics in Humans
COMPLETED · Phase 2
-
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
COMPLETED · Phase 2
-
A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.